Incyte Genomics Presentation to be Webcast by JP Morgan H&Q from its 20th Annual Healthcare Conference PALO ALTO, CA, January 4, 2002—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company announced today that its presentation at the JP Morgan H&Q Healthcare Conference will be webcast live by JP Morgan and can be accessed by registering at http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html. Paul A. Friedman, M.D., Chief Executive Officer and Robert Stein, M.D., Ph.D., President and Chief Scientific Officer will present an overview of the company and its business strategy. The presentation is scheduled to be delivered at 4:00 PM PST on Monday, January 7, 2002 from the Grand Ballroom of the Westin St. Francis Hotel in San Francisco. Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.